ADHD - Alcobra Ltd.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.446
-0.144 (-9.025%)
As of 11:40AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.590
Open1.550
Bid1.450 x 7700
Ask1.460 x 3600
Day's Range1.420 - 1.570
52 Week Range0.830 - 2.580
Volume936,532
Avg. Volume936,709
Market Cap39.87M
Beta1.30
PE Ratio (TTM)-1.90
EPS (TTM)-0.76
Earnings DateNov 15, 2017 - Nov 22, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.67
Trade prices are not sourced from all markets
  • ACCESSWIRE3 days ago

    Today's Research Reports on Stocks to Watch: Alcobra and Imprimis Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / October 20, 2017 / Alcobra headed higher on Thursday after the company's wholly-owned subsidiary Arcturus entered into a research collaboration and worldwide license agreement ...

  • SmarterAnalyst4 days ago

    Alcobra Ltd (ADHD) Stock Fires Up To The Roof; Here’s Why

    Alcobra Ltd (NASDAQ:ADHD) is a mover and shaker out on the Street today, with investors sparking the stock on an almost 40% upturn. Alcobra's wholly-owned subsidiary, Arcturus, announced that it has entered into a research collaboration and worldwide license agreement with Janssen Pharmaceuticals - a subsidiary of Johnson & Johnson. According to the agreement, the two companies will work together to develop and commercialize nucleic acid-based drug products for the treatment of Hepatitis B, using Arcturus’ UNA Oligomer chemistry and LUNAR™ lipid-mediated delivery platform.

  • GlobeNewswire4 days ago

    Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA Medicines

    SAN DIEGO, Oct. 19, 2017-- Arcturus Therapeutics, Inc., a leading RNA medicines company, announced today that it has entered into a research collaboration and worldwide license agreement with Janssen Pharmaceuticals, ...

  • GlobeNewswire17 days ago

    Arcturus Therapeutics, Inc. to Present at the Chardan Gene Therapy Conference

    SAN DIEGO, Oct. 06, 2017-- Arcturus Therapeutics, Inc., a privately held biotechnology company developing novel RNA medicines, today announced that Joseph Payne, President and Chief Executive Officer, ...

  • Should You Be Concerned About Alcobra Ltd’s (ADHD) Risks?
    Simply Wall St.18 days ago

    Should You Be Concerned About Alcobra Ltd’s (ADHD) Risks?

    If you are looking to invest in Alcobra Ltd’s (NASDAQ:ADHD), or currently own the stock, then you need to understand its beta in order to understand how it can affectRead More...

  • GlobeNewswire26 days ago

    Alcobra Ltd. and Arcturus Therapeutics, Inc. Agree to Merge

    Transaction to result in NASDAQ-listed company focused on developing novel RNA medicines and technologies Arcturus brings a proprietary and diverse pipeline with seven programs, four of which are funded ...

  • Associated Press2 months ago

    Alcobra reports 2Q loss

    On a per-share basis, the Tel Aviv, Israel-based company said it had a loss of 13 cents. The company's shares closed at $1.03. A year ago, they were trading at $4.91. _____ This story was generated by ...

  • GlobeNewswire2 months ago

    Alcobra Announces Second Quarter 2017 Financial Results and Provides Corporate Update

    TEL AVIV, Israel, Aug. 11, 2017-- Alcobra Ltd. today announced financial results for the three and six months ended June 30, 2017, and provided a corporate update.. Second Quarter and Recent Corporate ...

  • BioLine Rx (BLRX) Catches Eye: Stock Adds 5.2% in Session
    Zacks3 months ago

    BioLine Rx (BLRX) Catches Eye: Stock Adds 5.2% in Session

    BioLine Rx Ltd (BLRX) shares rise over 5% in the last trading session.

  • New Strong Buy Stocks for July 20th
    Zacks3 months ago

    New Strong Buy Stocks for July 20th

    New Strong Buy Stocks for July 20th

  • Accesswire4 months ago

    Featured Company News - Gilead's Vosevi Receives Positive Opinion from European CHMP; Set to Deliver Advanced Treatment for All HCV Genotypes

    Research Desk Line-up: Alcobra Post Earnings Coverage LONDON, UK / ACCESSWIRE / June 26, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Gilead Sciences, ...

  • Reuters4 months ago

    Shire wins U.S. approval for long-acting ADHD drug

    Shire has won U.S. approval for a long-acting attention deficit drug aimed at adolescents and adults, boosting its stock of medicines for the cognitive condition that affects millions of children and is being diagnosed more in older people. The U.S. Food and Drug Administration (FDA) green light for Mydayis follows good results for Shire's new hereditary angioedema drug and helps offset the setback of early generic competition to a Shire drug for ulcerative colitis. Shares in Dublin-based Shire rose 1.5 percent by 0800 GMT in London on Wednesday following the overnight FDA news.

  • Reuters5 months ago

    Swiss biotech NLS Pharma's ADHD drug succeeds in mid-stage study

    Swiss biotech NLS Pharma AG said on Wednesday mid-stage trial data showed that its drug to treat attention deficit hyperactivity disorder (ADHD) greatly reduced symptoms in adults, paving the way for a late-stage trial. ADHD is a chronic condition characterized by hyperactivity, impulsive behavior and a difficulty in sustaining focus. NLS' drug, mazindol, is a non-stimulant, but trial data showed it could be as effective as a stimulant.

  • Associated Press5 months ago

    Alcobra reports 1Q loss

    The Tel Aviv, Israel-based company said it had a loss of 13 cents per share. The company's shares closed at $1.13. A year ago, they were trading at $5.12. _____ This story was generated by Automated Insights ...

  • GuruFocus.com5 months ago

    Chuck Royce Continues to Buy These 10 Stocks

    Guru increased these holdings in the last 2 quarters

  • PR Newswire6 months ago

    Exodus Capital is Summoning an Extraordinary General Meeting

    RAMAT-GAN, Israel, April 12, 2017 /PRNewswire/ -- Exodus Capital L.P., together with its affiliates, are the beneficial owners of approximately 17% of the outstanding shares of Alcobra Ltd. (NASDAQ: ADHD") ("Alcobra" or the "Company") making us the Company's largest shareholder. Declining our request for an Extraordinary General Meeting is a clear violation of the Israeli Companies Law and Alcobra's own Articles of Association.

  • Accesswire7 months ago

    Tenax Therapeutics and Alcobra Find Rough Waters Ahead

    NEW YORK, NY / ACCESSWIRE / April 7, 2017 / Alcobra advanced 16.19% to close at $1.22 on Thursday. The stock traded between $1.03 and $1.25 on volume of 2.9 million shares traded. On April 5 th , the company ...

  • Business Wire7 months ago

    SHAREHOLDER ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit against Alcobra Ltd.

    Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Alcobra Ltd. . Investors who purchased or otherwise acquired shares between August 13, 2015 and January 17, 2017 inclusive , are encouraged to contact the firm in advance of the April 18, 2017 lead plaintiff motion deadline.